Subject: Obtaining a patent for GPR40 receptor agonists and their use in T2D treatment in the US
Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – confidential information, time: 4:42 PM
Content of the report:
Management Board of Celon Pharma S.A. (the “Company”) wishes to announce that on January 18, 2021, it received information that the Company was granted a patent covering GPR40 receptor agonists and their use in type diabetes treatment in the US.
The patent was granted by the United States Patent and Trademark Office and guarantees full legal protection of the compounds covered by the patent and their use in treating the above-mentioned conditions in the United States of America.
Celon Pharma S.A. develops GPR40 (CPL’280) in treatment of type 2 diabetes and diabetic neuropathies and that compound successfully completed phase I clinical trials.
The obtained patent protection reduces the risk associated with the project and increases the value of the Company's potential products in the therapeutic areas covered by patent protection.